September is Blood Cancer Awareness Month, and who better to speak about it than Aaron Gerds, MD, MS, Case CCC Deputy Associate Director for Clinical Research, member of the Developmental Therapeutics Program, and a hematologist-oncologist at Cleveland Clinic.
In an interview with OncLive, he discusses the evolving treatment landscape for myelofibrosis and how disease characteristics can help guide the selection of JAK inhibitors, explaining how factors including anemia and platelet counts can influence treatment decisions.
He also discusses emerging JAK inhibitor combinations and the potential for novel approaches to move treatment beyond symptom and spleen-volume control toward deeper, more durable responses.
The conversation highlights both the progress made in treating this rare blood cancer and the research questions that remain as investigators work to improve long-term outcomes. Read more below.